Objectives: This study examines C-reactive protein (CRP) levels predicting cardiovascular events (CVEs) among hormone therapy (HT) users and nonusers.
P
rospective epidemiologic studies have consistently demonstrated that higher levels of high-sensitivity Creactive protein (CRP) are independently associated with incident cardiac and vascular events in healthy men and women and add prognostic information to that conveyed by the Framingham risk score. 1<10 CRP levels are higher in women taking oral postmenopausal hormone therapy (HT) as compared with HT nonusers 11<13 ; however, whether or not the elevation in CRP that occurs with oral HT use is associated with increased risk in cardiovascular disease (CVD) remains unanswered.
14 A nested case-control study of women in the Women's Health Initiative Observational Study suggested that CRP is associated with future coronary risk irrespective of HT status at baseline, although risk estimates for the prediction of cardiovascular events (CVEs) were nonsignificant in HT users. 15 Similarly, CRP has been shown to be a linear predictor of CVE in HT nonusers in the Women's Health Study (WHS), 2 of HT users has not yet been conducted in this population. Current American Heart Association (AHA)/Centers for Disease Control and Prevention (CDC) recommendations regarding the use of CRP do not specify whether threshold cut-points for CRP are appropriate for HT users, but suggest that additional prospective studies are needed to more precisely define risk at various strata and to assure consistency in subgroup populations.
14 This study sought to determine whether CRP is a linear predictor of cardiovascular outcomes among HT users in the prospective WHS. In addition, we sought to evaluate whether existing AHA/CDC-recommended CRP threshold cut-points for low, average, and high cardiovascular risk (G1, 1-G3, and Q3 mg/L) predict cardiovascular risk in HT users as appropriately as in nonusers. 14 
METHODS

Study population and design
The WHS was a randomized, double-blind, placebocontrolled, 2 Â 2 factorial design trial of low-dose aspirin and vitamin E in the primary prevention of CVD and cancer conducted among 39,876 apparently healthy women 45 years or older.
17<21 Briefly, participants were enrolled between November 1992 and July 1995. For the purposes of our investigation, the study population was treated as an observational cohort of healthy adult women, for whom information regarding demographic, behavioral, medical, and lifestyle factors was collected via a questionnaire at baseline; at 12-, 36-, 60-, and 96-month intervals; and at the conclusion of the follow-up period. Menopause status (premenopausal, postmenopausal, dubious, or uncertain) and history of postmenopausal HT use (dichotomized to represent never/past use vs current use) were among the clinical variables reported. Women who used hormones that were not considered postmenopausal HT (such as oral progestogen or vaginal estrogen) were included in the never/past users category.
Participants were followed for a mean of 10 years for the occurrence of a first major CVE, defined as nonfatal myocardial infarction (MI), nonfatal ischemic stroke, coronary revascularization procedure (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty), or death from cardiovascular causes (CVD). A combined endpoint of CVD was used, after recent recommendations and the use of this endpoint by major clinical trials as being most informative for clinical practice 22 and due to limited power for any single endpoint category by strata of hormone use. MI was confirmed if symptoms met World Health Organization criteria and if the event was associated with abnormal levels of cardiac enzymes or diagnostic electrocardiographic changes. A confirmed stroke was defined as a new neurologic deficit of sudden onset that persisted for at least 24 hours. 23 The performance of either percutaneous coronary revascularization or coronary artery bypass grafting was confirmed by a review of hospital records. Deaths from cardiovascular causes were confirmed by a review of autopsy reports, death certificates, medical records, and information obtained from family members.
Before randomization, blood samples were collected in tubes containing EDTA from 28,345 study participants (71% participation rate) and stored in liquid nitrogen until the time of analysis. These samples underwent analysis of lipids and CRP in a core laboratory facility certified by the National Heart, Lung, and Blood Institute/CDC Lipid Standardization program. High-sensitivity CRP was measured using a validated immunoturbidometric method (Denka Seiken, Tokyo, Japan). Levels of total cholesterol and high-density lipoprotein cholesterol (HDL-C) were measured enzymatically on a Hitachi 911 autoanalyzer (Roche Diagnostics, Basel, Switzerland), and low-density lipoprotein cholesterol was determined directly (Genzyme, Cambridge, MA), as has been previously reported. 24 Of the samples received, 27,939 were evaluated. The 55 women for whom hormone status was not known were excluded from the analysis. The 1,093 transdermal HT users at baseline were also excluded, given the relative lack of change in CRP observed with transdermal use as compared with oral administration. 25<28 
Statistical analysis
Because oral HT increases levels of CRP, we first established population-based distributions for CRP among HT users and nonusers at the time of study entry. 29 Because CRP was not normally distributed, nonparametric univariate tests (Wilcoxon's rank sum test, two-sided t approximation) were used to compare the distributions of CRP between HT groups.
The associations of hormone use category (current use vs past/never use) with baseline demographic variables and cardiovascular risk factors were tested using univariable tests. The W 2 test was used for categorical predictors, and the Wilcoxon rank sum test was used for continuous predictors, given the nonnormality of their distribution.
To reduce misclassification error with respect to HT status, self-reported data regarding hormone status and HT regimens from the baseline questionnaire were compared with the 12-, 36-, 60-, and 96-month follow-up questionnaires, and women who changed hormone status during the course of study follow-up were censored at the first time point of self-reported change in hormone status. Censorship limited the number of CVE outcomes to 644 (278 in the 10,953 HT users and 366 in the 15,838 HT nonusers); by contrast, there were 907 CVE (354 in HT users, 552 in nonusers) in the uncensored cohort. total cholesterol to HDL-C, and history of use of cholesterollowering medication. All analyses were controlled for randomized treatment to aspirin, vitamin E, and A-carotene. Prediction of CVE outcomes by CRP was initially established by the use of quintiles, similar to those used in the previous WHS analysis. 2 Tertiles were then used for direct comparison with the established AHA/CDC (tertile) cut-points, which were evaluated in this study. Tests for trends across quintiles and tertiles of CRP and across the AHA/CDC cutpoints were assessed by entering a single ordinal term for each quantile or category based on the median CRP. In the evaluation of CRP as a continuous logarithm-transformed variable, the RR of incident CVE was compared between users and nonusers, and the likelihood ratio W 2 was compared for the models with and without the logarithm CRP (lnCRP) variable. In addition, effect modification of the AHA/CDC cut-points (CRP G1, 1-G3, and Q3 mg/L) by HT use in the prediction of CVE was evaluated by testing a formal interaction term (CRP [G1, 1-G3, and Q3 mg/L] * HT use). To compare risks between groups, a six-level variable with AHA/CDC categories and HT use categories was created, using a CRP level lower than 1 mg/L in nonusers as the referent group.
All P values are two-tailed, and 95% CIs were calculated. Data analysis was conducted using SAS statistical software version 9.1 (SAS Institute Inc., Cary, NC) and S-Plus software version 6.2 (Insightful Corp., Seattle, WA).
RESULTS
The median age at baseline for the 26,791 women included in this study was 52.9 years, and the median BMI was 24.9 kg/m 2 . At the time of study entry, 13,531 (50.5%) women had never used postmenopausal HT, 2,307 (8.6%) were past users, and 10,953 (40.9%) were current users. A comparison of demographic and clinical variables in the analysis cohort, stratified by HT use, is provided (Table 1) . HT users had higher CRP values and higher total and HDL cholesterol values, with lower low-density lipoprotein cholesterol and a lower ratio of total/HDL cholesterol. Of the 5,331 current HT users who used estrogen alone, 83.3% (4,442) used conjugated equine estrogens (CEEs). Of the 4,850 current HT users who used combination estrogen and progestogen, 83.8% (4,063) used CEE.
Baseline distributions of CRP differ significantly between HT users and nonusers (P G 0.001) as demonstrated in Table 2 . Baseline CRP level was 3 mg/L or higher in 29.3% of HT nonusers and 49.4% of HT users. The cut-point for the highest CRP quintile was more than 4.18 mg/L for HT nonusers compared with more than 6.44 mg/L for HT users.
When analyzed as a continuous logarithm-transformed variable, the multivariable relative risk for lnCRP was 1.27 (95% CI, 1.13-1.44) for HT nonusers and 1.22 (95% CI, 1.07-1.40) for HT users, which demonstrates that CVE risk increases with lnCRP in a similar fashion for both HT users and nonusers within their respective CRP distributions. A formal interaction term showed no difference in the two slopes (P = 0.62).
The crude, age-adjusted, and risk factorYadjusted relative risks of a first CVE, stratified by HT use and according to increasing quintiles of baseline CRP and to the AHA/CDC risk cut-points for CRP, are presented in Tables 3 and 4 , respectively. After adjustment for risk factors including age, postmenopause status, BMI, family history of MI, hypertension, diabetes, smoking, hyperlipidemia treatment, total/ HDL cholesterol ratio, and randomized treatment assignment, significant linear trends for future CVE were observed across quintiles for both HT nonusers and users, regardless of whether the CRP quintiles were based on HT users or nonusers (P trend G 0.02 for all quintiles) ( Adjusted for age, postmenopause status, body mass index, family history of myocardial infarction, hypertension, diabetes, smoking, hyperlipidemia treatment, and total/high-density lipoprotein cholesterol ratio. Table 4 demonstrates that a linear risk gradient was observed across the AHA/CDC clinical cut-points for CRP in HT nonusers (P trend G 0.001), but did not reach significance in HT users (P trend = 0.12). After risk factor adjustment, the RR of a first CVE in the AHA/CDC category for high (Q3 mg/L) risk was 1.96 (95% CI, 1.36-2.82) for HT nonusers and 1.42 (95% CI, 0.89-2.28) for HT users. However, the formal interaction term (CRP [G1, 1-G3, Q3 mg/L] * HT use) did not reach statistical significance (P interaction = 0.16).
To compare the risk associated with AHA/CDC CRP categories across HT use groups, we fit a model in which nonusers with a CRP level lower than 1 mg/L were the reference group (Fig. 1) . After adjusting for other risk factors including lipids, HT users with a CRP level of 3 mg/L or higher had an RR of 1.93 (1.38-2.69), whereas nonusers had an RR of 1.92 (1.35-2.72).
DISCUSSION
In this analysis of CRP among oral HT users and nonusers derived from an observational cohort of apparently healthy women, we found two key findings. First, we observed a linear relationship between CRP and future CVE for both HT users and HT nonusers in analyses using percentile cut-points defined separately for each group. There was generally a similar gradient of risk across AHA/CDC categories for nonusers and HT users, although the trend was not significant Adjusted for age, postmenopause status, body mass index, family history of myocardial infarction, hypertension, diabetes, smoking, hyperlipidemia treatment, and total/high-density lipoprotein cholesterol ratio.
FIG. 1.
Relative risks* for cardiovascular events for AHA/CDC CRP categories in 10,953 HT users and 15,838 nonusers, compared with a common referent group (nonusers with CRP G1 mg/dL). Follow-up censored at change in HT use status. *Adjusted for age, postmenopause status, body mass index, family history of myocardial infarction, hypertension, diabetes, smoking, hyperlipidemia treatment, total/high-density lipoprotein cholesterol ratio, and randomized treatment assignment. AHA, American Heart Association; CDC, Centers for Disease Control and Prevention; CRP, C-reactive protein; HT, hormone therapy. when examined in HT users as a group. However, after adjusting for lipids and other risk factor differences, HT users with a CRP level of higher than 3 mg/L had a nearly twofold increased risk in CVE, when compared with nonusers with a low CRP level (G1 mg/L). Taken together, these results suggests that the current AHA/CDC cut-points capture risk even for HT users.
Oral HT substantially raises CRP levels. For example, randomized treatment with oral CEEs (0.625 mg standard dose) led to a nearly twofold median change from baseline in CRP levels, 13 similar to what we observed in our population of predominantly CEE users (1.51 nonusers vs 2.95 mg/L in users). The current analyses confirm that CRP predicts cardiovascular risk in both HT users and nonusers. In prior analyses of participants in the Women's Health Initiative Observational Study, Pradhan et al 15 suggested that increasing concentrations of CRP were linearly associated with increasing odds of CVE across the full range of plasma values for both current HT users and nonusers; however, the odds ratios were nonsignificant for HT users, in whom outcomes were limited to 124 CVEs. 15 Similarly, prior analyses from the WHS have shown that among HT nonusers, there was a significant trend for risk of CVE across increasing quintiles of CRP (P trend G 0.001), whereas for HT users, the relationship seemed linear but had lower risk estimates with a nonsignificant trend (P trend = 0.08) when quintiles were based on HT nonusers. 2, 16 The current study design differed from the prior evaluation of the WHS population 2 in that we censored women when they changed HT status and adjusted for measured lipids. This study provides additional evidence that a linear relationship of CRP to CVD exists in both HT users and nonusers.
The major limitation of this study includes restriction to a single baseline measurement of CRP and lipids. In addition, HT use was self-selected, rather than randomized; thus, any comparison of HT users and nonusers should be interpreted with caution. In addition, we had limited power to be able to examine either coronary heart disease or stroke separately. However, CRP has strongly predicted coronary heart disease and stroke in this cohort previously. We have, however, provided a large and detailed evaluation of HT with respect to CRP and cardiovascular outcomes and have strengthened this evaluation by censoring women upon change in HT status to ensure accurate HT use classification.
CONCLUSIONS
In conclusion, we found a linear gradient of cardiovascular risk with increasing CRP for both HT users and nonusers. Clinically, our findings suggest that women with a CRP level of 3 mg/L or higher seem to be at higher cardiovascular risk even if they are HT users.
